Marguerite McDonald, MD
Ophthalmology · Oceanside, NYNPI 1356348452
Payments from drug & device makers
Across 1,231 payments — averaging $756.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$205K
- AbbVie$122K
- Oculus, Inc.$121K
- Sun Pharmaceutical Industries Inc.$94K
- Alcon$77K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$39K
- plus $273K from 38 others
What the payments were for
- Consulting fees$473,05053%
- Speaking & faculty fees$341,29438%
- Travel & lodging$39,2714%
- Food & beverage$38,7154%
- Education$3050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIIDRA$173,015
- MIEBO$142,353
- CEQUA$91,105
- Keratograph$65,000
- VUITY$44,798
- Prokera$31,671
- AmnioGraft$31,671
- TRYPTYR$31,083
- OCULUS Pentacam$30,667
- Oxervate$26,747
- EYSUVIS$19,963
- Systane$18,655
- AmnioGuard$18,125
- LOTEMAX SM$17,558
- OPHTHALMIC INSTRUMENTS$16,202
- Pentacam$15,000
- TYRVAYA$14,965
- ILUX$14,115
- Keratograph 5M$10,000
- TEPEZZA$9,916
How this compares
$931,401 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 35 | $1,309,947 |
| XiidraLifitegrast | 477 | $599,720 |
| RestasisCyclosporine | 427 | $551,202 |
| MieboPerfluorohexyloctane/Pf | 151 | $152,891 |
| Cyclosporine | 153 | $75,098 |
| Bepotastine Besilate | 265 | $48,010 |
| TyrvayaVarenicline Tartrate | 60 | $38,651 |
| ErythromycinErythromycin Base | 875 | $31,940 |
| Restasis MultidoseCyclosporine | 32 | $30,116 |
| XdemvyLotilaner | 13 | $23,380 |
| RhopressaNetarsudil Mesylate | 40 | $22,093 |
| LumiganBimatoprost | 30 | $15,357 |
| CequaCyclosporine | 15 | $14,906 |
| ZirganGanciclovir | 20 | $9,121 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 35 | $9,034 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $33,208 | $1,309,94735 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Zirgan, Vyzulta | $205,072 | $767,927662 claims |
| AbbVieRestasis, Restasis Multidose, Lumigan | $122,437 | $596,675489 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $15,824 | $38,65160 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $5,210 | $23,38013 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $36 | $22,09340 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $93,590 | $14,90615 claims |
| AlconSimbrinza | $76,920 | $9,03435 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCBepreve | $39,458 | $4,02615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Oceanside
- Douglas JabsNew York$24.3M
- David RubaltelliBrooklyn$8.9M
- Philip FerroneGreat Neck$5.8M
- Eric DonnenfeldGarden City$2.6M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
- Richard SpaideNew York$1.7M
- Paul HartmanRochester$1.6M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.